Press release article from our research archive:

Mylan Announces Tentative FDA Approval for Ondansetron Orally Disintegrating Tablets, USP.

PITTSBURGH, Feb. 26 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. today announced that Mylan Pharmaceuticals Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ondansetron Orally Disintegrating Tablets USP, 4mg and 8mg strengths.

Ondansetron Orally Disintegrating Tablets are the generic version of GlaxoSmithKline's Zofran ODT(R) Tablets, which had U.S. sales of approximately $314 million for the same strengths for the 12-month period ending Dec. 31, 2006, according to IMS ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!